iCo Therapeutics, Inc. engages in the business of identification, development and commercialization of drug candidates for the treatment of sight- and life-threatening diseases. Its products include iCo-008 and oral AmpB delivery system. The company was founded by Andrew J. Rae, John G. Clement and William John Meekison on February 15, 2005 and is headquartered in Vancouver, CA.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone778-802-9806
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/23/2019 (Estimated)
OptionableNot Optionable
iCo Therapeutics (OTCMKTS:ICOTF) Frequently Asked Questions
What is iCo Therapeutics' stock symbol?
iCo Therapeutics trades on the OTCMKTS under the ticker symbol "ICOTF."
When is iCo Therapeutics' next earnings date?
Has iCo Therapeutics been receiving favorable news coverage?
Media coverage about ICOTF stock has been trending positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. iCo Therapeutics earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of iCo Therapeutics' key competitors?
Some companies that are related to iCo Therapeutics include Innovus Pharmaceuticals (INNV), X T L Biopharmaceuticals (XTLB), ERBA Diagnostics (ERBA), International Stem Cell (ISCO), Endonovo Therapeutics (ENDV), Cyclacel Pharmaceuticals (CYCC), MYOS (MYOS), NeuroVive Pharmaceutical (NEVPF), Cellectar Biosciences (CLRB), Dare Bioscience (DARE), Diffusion Pharmaceuticals (DFFN), Regulus Therapeutics (RGLS), Peak Pharmaceuticals (PKPH), Vital Therapies (VTL) and MusclePharm (MSLP).
What other stocks do shareholders of iCo Therapeutics own?
Who are iCo Therapeutics' key executives?
iCo Therapeutics' management team includes the folowing people:
- Andrew J. Rae, President, Chief Executive Officer & Director
- Eugene Williams, Chief Operating Officer
- Michael Liggett, Chief Financial Officer, Secretary & Director
- Peter Hnik, Chief Medical Officer
How do I buy shares of iCo Therapeutics?
Shares of ICOTF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is iCo Therapeutics' stock price today?
One share of ICOTF stock can currently be purchased for approximately $0.0553.
How big of a company is iCo Therapeutics?
iCo Therapeutics has a market capitalization of $5.06 million.
What is iCo Therapeutics' official website?
How can I contact iCo Therapeutics?
iCo Therapeutics' mailing address is 777 Hornby Street 6th Floor, Vancouver A1, V6Z 1S4. The biotechnology company can be reached via phone at 778-802-9806 or via email at [email protected]
MarketBeat Community Rating for iCo Therapeutics (OTCMKTS ICOTF)
MarketBeat's community ratings are surveys of what our community members think about iCo Therapeutics and other stocks. Vote "Outperform" if you believe ICOTF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICOTF will underperform the S&P 500 over the long term. You may vote once every thirty days.
